Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
TCRX
$0.22
+0.00%
TCRX
· TScan Therapeutics, Inc.
$0.22
+0.00 (+0.00%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, substantial doubt about the Company's ability to continue as a going concern exists. ... These conditions raise substantial doubt about the Company's ability to continue as a going concern. ... Therefore, substantial doubt about the Company's ability to continue as a going concern has not been alleviated.”View the 10-Q filed Aug 12, 2026
Market Cap
$14.91M
Shares
67.78M
Volume · Oct 21
689.45K
Avg daily vol (3M)
771.88K
All webcasts
Earnings call · FY2025 Q1
TScan Therapeutics, Inc. (TCRX) Q1 2025 Earnings Call
Revenue
$2.17M
+283.6% YoY
Diluted EPS
-$0.26
Net income
-$34.13M
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed May 6, 2025 · complete as-filed document
SEC periodic report
10-Q report
Filed May 6, 2025 · complete as-filed document